bioAffinity Technologies, Inc.
Health Care · USD
Price
$3.13
Cap
$14M
Earnings
1/4 beat
30d Trend
-6%
Near 52-week lows — potential value or falling knife
Consensus: Hold
Earnings history
Q4 2025
BEAT
-1.11 vs -2.7
Q3 2025
MISS
-4.74 vs -2.7
Q2 2025
MISS
-5.1 vs -3
Q1 2025
MET
-4.8 vs -4.8
Key macro factors
Advancements in AI and machine learning in healthcare, as the company's diagnostic platform utilizes AI for automated analysis.
The increasing global focus on early cancer detection and non-invasive diagnostic methods to improve patient outcomes and reduce healthcare costs.
Changes in the regulatory landscape for Laboratory Developed Tests (LDTs), which could impact the commercialization and adoption of CyPath® Lung.
bioAffinity Technologies, Inc. is a biotechnology company that focuses on noninvasive diagnostics and the early detection of lung cancer and other lung diseases, leveraging flow cytometry and automated analysis developed by machine learning.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.